News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 10, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement
Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented efficacy and safety outcomes in a subgroup of patients from the NALA trial who had central nervous system (CNS)
NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer
Savara Provides Pipeline and Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve
NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated results from the ongoing Phase II SUMMIT trial of neratinib at the 2020 Virtual San Antonio Breast Cancer
Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the start
Transgene to Present Phase 1b/2 Trial Results of TG4001 in Combination with avelumab in Advanced HPV-Positive Cancers at ESMO IO 2020
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will present the Phase 1b/2 trial results of TG4001, a HPV16
Transgene Appoints Hedi Ben Brahim as Chairman and Chief Executive Officer
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that the Board, at its meeting today, approved the
Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has prevailed in final appeal proceedings brought against its licensed European patent EP Patent 1848414
Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations will be
Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK in
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that pursuant to the terms of that previously announced Exchange and Purchase Agreement, dated as of November 4, 2020, by and between Clovis
Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences:
Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that Steve
The Boston Globe Names Deciphera a Top Place to Work for 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, has been named one of the
Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that the Company’s Compensation Committee granted
NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that a pre-recorded fireside chat with President and Chief Executive Officer Patrick J. Mahaffy will be available next week for replay as part
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 10 abstracts that will be presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS)
Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer
Regulatory News:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205 – the “Company”) (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies
NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy
NANOBOTIX (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced positive new in vivo
Savara to Present at the Jefferies Virtual London Healthcare Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on